english.prescrire.org > Spotlight > 100 most recent > In the December issue of Prescrire International: Tibolone and breast cancer: evidence of increased risk

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

In the December issue of Prescrire International:
Tibolone and breast cancer: evidence of increased risk

FREE DOWNLOAD Tibolone increases the risk of breast cancer and stroke. It is better to avoid it.
Full text available for free download.

Abstract

  • Tibolone is a synthetic steroid marketed for the treatment of menopausal symptoms.
     
  • A cohort study of women with no history of breast cancer showed that tibolone was associated with an increased risk of breast cancer. In women with a history of breast cancer, a placebo-controlled trial showed a higher risk of breast cancer recurrence with tibolone.
     
  • A placebo-controlled trial of half the standard dose of tibolone showed no increased risk of breast cancer but was interrupted due to an increased risk of stroke.
     
  • In practice, it is better simply not to use tibolone. 

 ©Prescrire December 2010

"Tibolone and breast cancer" Prescrire Int 2010 ; 19 (111) : 281. (Pdf, free)
Download the full review
Pdf, free